# Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer?

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/sabcsfuturefocus/123901) · 2026-11-16 · Medicine
Page: https://themorning.science/story/can-adjuvant-pembrolizumab-improve-outcomes-in-triple-negative-breast-cancer-e8454f80e0289dde
Kind: research · Impact: medium

## In brief

- MedPage Today published a video preview by Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care, on the phase III SWOG-S1418/NRG Oncology BR006 trial.
- The trial studies adjuvant pembrolizumab (Keytruda) in triple-negative breast cancer.
- The source is a short preview snippet and does not report the trial's results.

## Why it matters

Triple-negative breast cancer is an aggressive subtype with limited targeted options, so results from a phase III trial of adjuvant pembrolizumab could bear on post-surgery treatment decisions.

## Coverage

- [Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer?](https://www.medpagetoday.com/meetingcoverage/sabcsfuturefocus/123901) — MedPageToday.com - medical news for physicians, 2026-11-16

Tags: breast cancer, immunotherapy, clinical trials, oncology, pembrolizumab

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
